Aytu BioPharma, Inc. (LON:0A8M)

London · Delayed Price · Currency is GBP · Price in USD

2.200

+0.520 (30.95%)

At close: May 16, 2025

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Rx Segment	66.38M	65.18M		61.12M	32.68M	17.25M
Rx Segment Growth	1.84%	-		87.04%	89.45%	135.64%
Consumer Health	-	-		35.55M	32.95M	10.38M
Consumer Health Growth	-	-		7.87%	217.38%	-
Total	66.38M	65.18M		96.67M	65.63M	27.63M
Total Growth	1.84%	-		47.29%	137.52%	277.49%

Revenue by Geography

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
United States	66.38M	65.18M		94.61M	60.69M	24.98M
United States Growth	1.84%	-		55.89%	142.94%	286.57%
International	-	-		2.06M	4.95M	2.65M
International Growth	-	-		-58.28%	86.46%	209.09%
Total	66.38M	65.18M		96.67M	65.63M	27.63M
Total Growth	1.84%	-		47.29%	137.52%	277.49%

Source: S&P Global Market Intelligence.